DECISiVE: DECISIve - DiagnosE Using the Central veIn SIgn v1.0

Sponsor
Nottingham University Hospitals NHS Trust (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05533905
Collaborator
(none)
115
1
46.9
2.5

Study Details

Study Description

Brief Summary

DECISIve - DiagnosE using the Central veIn SIgn. A prospective diagnostic superiority study comparing T2* MRI and lumbar puncture in patients presenting with possible Multiple Sclerosis

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Lumbar puncture
  • Diagnostic Test: MRI

Detailed Description

There is currently no agreement on the best way to diagnose Multiple Sclerosis (MS). Frequently, people suspected of having MS have a standard MRI scan and undergo a 'lumbar puncture' (a thin needle is inserted between the bones in the lower spine). Patients often report they find it painful and it can cause unintended complications requiring hospitalisations or time off work to recover.

Although the fluid taken during a lumbar puncture can show evidence of disease, this is not always the case. We do not find abnormalities in everyone who has MS but some people with conditions that can mimic MS, but need very different treatment, have similar lumbar puncture abnormalities. Both of these problems can lead to misdiagnosis.

A new MRI scan allows us to see small veins that run through damaged areas of the brain in people with MS. It has been shown that this is a specific finding to MS, seldom seen in other conditions. It is not painful and carries few or no risks.

This research aims to change the way people are diagnosed with MS and reduce the number of lumbar punctures used. Our team will recruit a large number of people from different hospitals whose doctors suspect they may have MS. We will invite them to have the new eight-minute MRI scan. After 18 months, we will find out what diagnosis is eventually reached and compare this to the finding of the new scan. We will compare the accuracy, speed, costs and acceptability of the different tests needed to make a diagnosis of MS and establish if most lumbar punctures can be replaced by a slightly longer MRI scan. This research could provide the NHS with a scientific approach to diagnose MS which is safer, more cost effective and importantly, more acceptable to patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
115 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
DECISIve - DiagnosE Using the Central veIn SIgn. A Prospective Diagnostic Superiority Study Comparing T2*MRI and Lumbar Puncture in Patients Presenting With Possible Multiple Sclerosis.
Actual Study Start Date :
Dec 9, 2019
Anticipated Primary Completion Date :
Nov 6, 2023
Anticipated Study Completion Date :
Nov 6, 2023

Outcome Measures

Primary Outcome Measures

  1. Is T2* MRI scan more sensitive than lumbar puncture with oligoclonal band testing for diagnosing MS at the time of first clinical presentation? [18 months]

    Comparison of MRI and lumbar puncture in diagnosing MS.

Secondary Outcome Measures

  1. Is there a significant difference between the specificity of each diagnostic test in this cohort? [18 months]

    Is there a difference in the quality of the diagnostic tests.

  2. Is there a significant difference between the sensitivity and specificity of the 'rule of six' proposed in Mistry et al. 2016 and lumbar puncture with oligoclonal bands? [18 months]

    Comparison with past research

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Presentation with a typical clinically isolated syndrome (Thompson et al. 2017) for diagnostic evaluation of MS.
Exclusion Criteria:
  1. Fulfils the diagnosis of MS, as defined by the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2017).

  2. Unwilling or unable to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that, in the opinion of the PI, is likely to affect the participant's ability to comply with the study protocol.

  3. Unable to provide informed consent.

  4. Contraindication or inability to undergo MRI due to metal or metal implants, pregnancy, claustrophobia, pain, spasticity, or excessive movement related to tremor.

  5. Acute COVID-19 infection at time of face-to-face interactions during study (unless investigations can be delayed until considered safe by the responsible clinician and PI) either diagnosed clinically or by acute infection testing

  6. Participant required to self-isolate at time of face-to-face interactions during study (unless investigations can be delayed until considered safe by the responsible clinician and PI) due to COVID-19 exposure, shielding due to medical advice, public health advice or governmental advice/laws.

Contacts and Locations

Locations

Site City State Country Postal Code
1 NUH NHS Trust Nottingham United Kingdom NG7 2UH

Sponsors and Collaborators

  • Nottingham University Hospitals NHS Trust

Investigators

  • Principal Investigator: Nikos Evangelou, NUH NHS Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nottingham University Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT05533905
Other Study ID Numbers:
  • 19NS022
First Posted:
Sep 9, 2022
Last Update Posted:
Sep 9, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 9, 2022